Evidence map›Paper›PMID 38264673›Full record

ArticleEthiopian medical journal2022

Mental wellbeing during the time of COVID-19 pandemic: A national pilot survey in Ethiopia.

Bethelhem Fekadu, Medhin Selamu, Eyerusalem Getachew, Hanna Negussie, Sewit Timothewos, Winini Belay, Abigiya Wondimagegnehu, Tigist Eshetu, Tigest Ajeme, Kehabtimer Shiferaw and 4 more

Abstract read
In one paragraph

Article in Ethiopian medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bethelhem FekaduAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Medhin SelamuAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Eyerusalem GetachewAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Hanna NegussieAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Sewit TimothewosAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Winini BelayAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Abigiya WondimagegnehuAddis Ababa University, College of Health Sciences, School of Public Health, Addis Ababa, Ethiopia.
Tigist EshetuAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Tigest AjemeAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Kehabtimer ShiferawAddis Ababa University, College of Health Sciences, School of Public Health, Addis Ababa, Ethiopia.
Tsegahun ManyazewalAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Abebaw FekaduAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Girmay MedhinAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.
Charlotte HanlonAddis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), Addis Ababa, Ethiopia.

Funding

Ethiopia-Emory TB Research Training ProgramD43TW009127 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Kidist Bobosha · 2013 to 2026
$3.4M
FIC NIH HHS D43 TW009127Wellcome Trust
6 · The paper itself

Abstract

Introduction: The Coronavirus Disease 2019 (COVID-19) pandemic substantially disrupts population health and wellbeing globally, while little is known about the effect on mental wellbeing in developing countries. This study aimed to assess the impact of COVID-19 on mental wellbeing of individuals and households in Ethiopia. Methods: A cross-sectional, national pilot survey was conducted through phone interviews from September to November 2021. Mental wellbeing and disability were assessed using a questionnaire adapted from the 5-item World Health Organization Wellbeing Index (WHO-5), the Oslo Social Support Scale (OSSS-3), and the WHO Disability Assessment Scale (WHODAS 2.0). Results: A total of 614 adults completed the pilot survey. The mean age was 36 years (standard deviation 11) and 71.7% were male. Mental wellbeing was poor in 218 (35.5%) participants. The most important predictors for poor mental wellbeing were rural residence (Adjusted Odds Ratio [AOR] 1.89; 95% CI 1.14, 3.14; p=0.012), perceived COVID-19 risk (AOR 1.75; 95% CI 1.18, 2.60; p=0.005), household stress (AOR 2.09; 95% CI 1.31, 3.34; p=0.002), experience of symptom of COVID-19 in the household (AOR 2.14; 95% CI 1.13, 4.04; p=0.019), and poor social support (AOR 2.43; 95% CI 1.51, 3.91; p<0.001). Conclusion: The study provides evidence that COVID-19 had a significant adverse impact on the mental wellbeing of individuals and households in Ethiopia. Further studies are needed to understand in detail the implications of the pandemic and interventions needed to keep mental wellbing of citizens.

Indexed as

COVID-19disabilityEthiopiamental healthmental wellbeing

Identifiers

PMID38264673
PMCPMC10805474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.